SeLux Diagnostics develops universal synthetic amplifier technology equipment for antibiotic susceptibility testing and diagnostics. The Company's Next Generation Phenotyping (NGP) system provides virtually instantaneous AST results, fast-tracking targeted patient therapies so patients can receive the treatments they need. The platform is driven by SeLux’s proprietary assay, which differentiates antibiotic-induced bacterial growth modes with a surface-binding fluorescent amplifier.